170 related articles for article (PubMed ID: 27207188)
1. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.
Dombret H; Thomas X; Chevallier P; Nivot E; Reitan J; Barber B; Barlev A; Mohty M
J Med Econ; 2016 Nov; 19(11):1034-1039. PubMed ID: 27207188
[TBL] [Abstract][Full Text] [Related]
2. Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.
Maertens J; Graux C; Breems D; Havelange V; Wittnebel S; Strens D; Hoefkens C
Acta Clin Belg; 2017 Dec; 72(6):429-433. PubMed ID: 28406385
[TBL] [Abstract][Full Text] [Related]
3. Burden of hospitalization in relapsed acute lymphoblastic leukemia.
Barlev A; Lin VW; Song X
Curr Med Res Opin; 2016 Jul; 32(7):1209-12. PubMed ID: 26960412
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; Boluda B; Rodríguez-Veiga R; Cano I; Acuña-Cruz E; Blanco A; Marco-Ayala J; de la Puerta R; Díaz-González Á; Piñana JL; Sanz J; Sempere A; Cervera J; Barragán E; Sargas C; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Eur J Haematol; 2021 May; 106(5):724-733. PubMed ID: 33609315
[TBL] [Abstract][Full Text] [Related]
5. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States.
Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Cong Z
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):573-580. PubMed ID: 29923428
[TBL] [Abstract][Full Text] [Related]
6. Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain.
Boluda B; Rodríguez-Veiga R; Martínez-Cuadrón D; Lorenzo I; Sanz J; Regadera A; Sempere A; Senent L; Cervera JV; Solves P; Reitan J; Gea S; Sanz MA; Montesinos P
Pharmacoecon Open; 2019 Jun; 3(2):229-235. PubMed ID: 30324566
[TBL] [Abstract][Full Text] [Related]
7. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia].
Bao L; Jiang B; Huang XJ; Wang DB; Qiu JY; Lu XJ; Chen H; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):31-4. PubMed ID: 15946506
[TBL] [Abstract][Full Text] [Related]
11. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.
Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J
Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793
[TBL] [Abstract][Full Text] [Related]
12. Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia.
Kako S; Kanamori H; Kobayashi N; Shigematsu A; Nannya Y; Nakamae M; Shigeno K; Suzukawa K; Takeuchi M; Tsuzuki M; Usuki K; Hatanaka K; Ogawa K; Mitani K; Nawa Y; Hatta Y; Mizuno I; Kanda Y
Br J Haematol; 2013 Apr; 161(1):95-103. PubMed ID: 23368421
[TBL] [Abstract][Full Text] [Related]
13. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
14. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
15. GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia.
Camera A; Annino L; Chiurazzi F; Fazi P; Cascavilla N; Fabbiano F; Marmont F; Di Raimondo F; Recchia A; Vignetti M; Rotoli B; Mandelli F
Haematologica; 2004 Feb; 89(2):145-53. PubMed ID: 15003889
[TBL] [Abstract][Full Text] [Related]
16. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Ribera JM; Fielding AK; Advani A; Bassan R; Chia V; Doubek M; Giebel S; Hoelzer D; Ifrah N; Katz A; Kelsh M; Martinelli G; Morgades M; O'Brien S; Rowe JM; Stieglmaier J; Wadleigh M; Kantarjian H
Haematologica; 2016 Dec; 101(12):1524-1533. PubMed ID: 27587380
[TBL] [Abstract][Full Text] [Related]
17. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
18. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
19. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.
Aldoss I; Yang D; Malki MMA; Mei M; Mokhtari S; Artz A; Cao T; Salhotra A; Ali H; Aribi A; Khaled S; Arslan S; Sandhu K; Koller P; Mansour J; Spielberger R; Stein A; Snyder D; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
Transplant Cell Ther; 2021 Mar; 27(3):255.e1-255.e9. PubMed ID: 33781525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
